共 50 条
- [41] Association of LAG-3 expression in circulating T cells and response to combination temozolomide (TMZ) and nivolumab (NIVO) in advanced neuroendocrine neoplasms (NENs): Results from an investigator-initiated phase 2 trial.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Sukrithan, VineethBenner, BrookeWei, LaiGoyal, AshimaZhou, YeSuffren, Sheryl-AnnPilcher, CarlyChristenson, GwenCurtis, NancySchwarz, EmilySavardekar, HimanshuNorman, RuthannKleiber, BarbaraWesolowski, RobertOtterson, Gregory AlanVerschraegen, Claire F.Carson, William EdgarShah, Manisha H.Konda, BhavanaOwen, Dwight Hall
- [42] Impact of Immune response-associated gene polymorphisms on tumor response in rectal cancer patients treated with capecitabine plus /- oxaliplatine and radiation in the ACCORD-12/PRODIGE-2 phase III trial.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Boige, ValerieMollevi, CarolineChaput, NathalieGourgou, SophieAzria, DavidSeitz, Jean-FrancoisBigot, LudovicJuzyna, BeataMiran, IsabelleGerard, Jean-PierreLaurent-Puig, Pierre
- [43] Efficacy and safety of QL1706, a novel dual immune checkpoint blockade containing a mixture of anti-PD1 IgG4 and anti-CTLA4 IgG1 antibodies, for advanced cervical cancer: Cohort data from a phase 1b trial.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Liu, JihongLiu, NaifuWang, DanboLi, DapengFang, Cheng
- [44] Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trialLANCET ONCOLOGY, 2015, 16 (03): : 257 - 265Rizvi, Naiyer A.Mazieres, JulienPlanchard, DavidStinchcombe, Thomas E.Dy, Grace K.Antonia, Scott J.Horn, LeoraLena, HerveMinenza, ElisaMennecier, BertrandOtterson, Gregory A.Campos, Luis T.Gandara, David R.Levy, Benjamin P.Nair, Suresh G.Zalcman, GerardWolf, JuergenSouquet, Pierre-JeanBaldini, EdittaCappuzzo, FedericoChouaid, ChristosDowlati, AfshinSanborn, RachelLopez-Chavez, ArielGrohe, ChristianHuber, Rudolf M.Harbison, Christopher T.Baudelet, ChristineLestini, Brian J.Ramalingam, Suresh S.
- [45] Broad Antibody and Cellular Immune Response From a Phase 2 Clinical Trial With a Novel Multivalent Poxvirus-Based Respiratory Syncytial Virus VaccineJOURNAL OF INFECTIOUS DISEASES, 2021, 223 (06): : 1062 - 1072Jordan, ElkeLawrence, Steven J.Meyer, Thomas P. H.Schmidt, DarjaSchultz, StephanieMueller, JuttaStroukova, DariaKoenen, BrigitteGruenert, RobertSilbernagl, GuenterVidojkovic, SanjaChen, Liddy M.Weidenthaler, HeinzSamy, NathalyChaplin, Paul
- [46] PHASE 2 TRIAL OF NEOADJUVANT AND ADJUVANT PD-1 CHECKPOINT BLOCKADE IN LOCAL-REGIONALLY ADVANCED, RESECTABLE HNSCC INDICATES PATHOLOGICAL RESPONSE IS ASSOCIATED WITH HIGH DISEASE-FREE SURVIVALJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A484 - A485Wise-Draper, TrishaGulati, ShuchiTakiar, VinitaPalackdharry, SarahWorden, FrancisOld, MatthewKaczmar, JohnDunlap, NealHinrichs, BenjaminBell, DianaPatil, YashRiaz, Muhammad KashifWeatherford, LayneHamilton, AubreyLanverman, SheenaMierzwa, MichelleCasper, KeithMark, JonathanTang, AliceZender, ChadGillenwater, AnnMedvedovich, MarioLee, J. JackJandarov, RomanGillison, Maura
- [47] An assessment of disease features and immune response in breast cancer patients that did not recur after receiving HER2 peptide, AE37 vaccine in a randomized phase II trial.JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)Hale, Diane F.Perez, Sonia A.Vreeland, Timothy J.Trappey, Alfred F.Dabney, Raetasha SheavetteBerry, John S.Ardavanis, AlexandrosSears, Alan K.Papamichail, MichaelClifton, Guy T.Pappou, EfiPatil, RiteshAnastasopoulou, EleftheriaPonniah, SathibalanShumway, Nathan M.Peoples, George EarlMittendorf, Elizabeth Ann
- [48] Quality of life (QoL) of OSE2101 in patients with HLA-A2+non-small cell lung cancer (NSCLC) after failure to immune checkpoint inhibitors (IO): Final data of phase 3 Atalante-1 randomized trial.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Besse, BenjaminCampelo, Rosario GarciaCobo-Dols, ManuelQuoix, Elisabeth AnneMadroszyk, AnneFelip, EnriquetaCappuzzo, FedericoDenis, FabriceHilgers, WernerRomano, GiampieroDebieuvre, DidierGaletta, DomenicoBaldini, EdittaRamirez, Santiago ViteriPhan, Minh DucSchuette, WolfgangZer, AlonaVasseur, BerangereDziadziuszko, RafalGiaccone, Giuseppe
- [49] NeoRad(Low): A phase 2 trial of neoadjuvant (NA) ipilimumab plus nivolumab (ipi plus nivo) with low dose stereotactic body radiation therapy (SBRT) as an immune stimulant in patients with resectable stage IB-III non-small cell lung cancer (NSCLC)JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)DiPetrillo, Thomas A.Garcia-Moliner, MariaKoffer, PaulHepel, Jaroslaw T.Khan, HinaKhurshid, HumeraAbbas, AbbasBirnbaum, Ariel E.Olszewski, Adam J.Ferreira, CheyenneHassinger, FaithMcCormick, Michele CarlinGiesing, HannahRodrigues, NunoRosati, VallerieWood, RoxanneWebber, AmyMaleki, SaraAzzoli, Christopher G.
- [50] Phase 2 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for progressive disease after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell (mcc) renal cell carcinoma (RCC): Results by independent imaging review and subgroup analysesASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 133 - 133Lee, Chung-HanShah, Amishi YogeshHsieh, James J.Rao, ArpitPinto, AlvaroBilen, Mehmet AsimCohn, Allen LeeDi Simone, ChristopherShaffer, David R.Sarrio, Regina GironesRibe, Sara GunnestadWu, JaneSchmidt, EmmettKubiak, PeterOkpara, ChinyereSmith, Alan D.Young, LouiseMotzer, Robert J.